Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The present investigation reports an extensive evaluation of in vitro and in vivo anticancer efficacy of orally administered doxorubicin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Dox-NPs) in a breast cancer induced animal model. Spherically shaped Dox-NPs were prepared with an entrapment efficiency and particle size of 55.40 ± 2.30% and 160.20 ± 0.99 nm, respectively, and freeze-dried with 5% trehalose using stepwise freeze-drying. Cytotoxicity, as investigated on C127I cell line, revealed insignificant differences between the IC(50) of free Dox and Dox-NPs treated cells in the first 24 h, while higher cytotoxicity was demonstrated by Dox-NPs, following 72 h of incubation. Confocal laser scanning microscopy (CLSM) imaging corroborated that nanoparticles were efficiently localized into the nuclear region of C127I cells. The cellular uptake profile of Dox-NPs revealed both time and concentration dependent increases in the Caco-2 cell uptake as compared to the free Dox solution. Further, Dox-NPs significantly suppressed the growth of breast tumor in female Sprague-Dawley (SD) rats upon oral administration. Finally, orally administered Dox-NPs showed a marked reduction in cardiotoxicity when compared with intravenously injected free Dox as also evident by the increased level of malondialdehyde (MDA), lactate dehydrogenase (LDH), and creatine phosphokinase (CK-MB) and reduced levels of glutathione (GSH) and superoxide dismutase (SOD). The reduced cardiotoxicity of orally administered Dox-NPs was also confirmed by the major histopathological changes in the heart tissue after the treatments of intravenously injected free Dox and orally delivered Dox-NPs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“when the efficacy of WGA-coated allergen-loaded microspheres was evaluated in birch pollen-sensitized mice, oral treatment did not induce an allergen-specific isotype switch towards IgG2a or the production of the Th1 cytokine IFN-γ in comparison to gavages of plain microspheres [74].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [74]
In the citing paper
“in a 7,12-dimethylbenz[a]anthracene-induced breast cancer rat model, oral administration of doxorubicin loaded PLGA NPs revealed a higher antitumor efficacy as a result of enhanced bioavailability, tumor permeation and retention effect [74].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [74]
In the citing paper
“incorporation of doxorubicin into PLGA nanospheres significantly reduced the doxorubicin-induced cardiotoxicity [74].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [74]
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Freeze-drying of nanoparticles: Formulation, process and storage considerations
ABDELWAHED, W., DEGOBERT, G., STAINMESSE, S., & FESSI, H. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.017 · Cited by 1,611
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Yin Win, K., & Feng, S.-S. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.07.050 · Cited by 1,452
Govender, T. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00116-3 · Cited by 1,008
Artursson, P. (1990) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600790604 · Cited by 844
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776
Chitosan nanoparticles as delivery systems for doxorubicin
Janes, K. A., Fresneau, M. P., Marazuela, A., Fabra, A., & Alonso, M. J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00294-2 · Cited by 721
Research works printed but not linked: 3
- Bardelmeijer H. A., 2000, Clin. Cancer Res., 6, 4416
- Rehm S., 1990, Am. J. Pathol., 136, 575
- Ballinger J. R., 1996, J. Nucl. Med., 37, 1578
Cited by
Oral delivery of anticancer drugs: Challenges and opportunities
Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.020 · Cited by 499
Self-citationJain, A. K., Thanki, K., & Jain, S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400311j · Cited by 235
Self-citationHSA Coated Iron Oxide Nanoparticles as Drug Delivery Vehicles for Cancer Therapy
Quan, Q., Xie, J., Gao, H., Yang, M., Zhang, F., Liu, G., Lin, X., Wang, A., Eden, H. S., Lee, S., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200006f · Cited by 223
Jain, S., Rathi, V. V., Jain, A. K., Das, M., & Godugu, C. (2012) · Nanomedicine · doi:10.2217/nnm.12.31 · Cited by 174
Self-citationAgrawal, A. K., Harde, H., Thanki, K., & Jain, S. (2014) · Biomacromolecules · doi:10.1021/bm401580k · Cited by 170
Self-citation
Metadata
- Authors
- Jain, A. K., Swarnakar, N. K., Das, M., Godugu, C., Singh, R. P., Rao, P. R., & Jain, S.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- Corresponding author
- Jain, Sanyog
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-05-25
- Volume
- 8
- Issue
- 4
- Pages
- 1140-1151
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2332972932
- Cited by
- 89
- References
- 52
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 12 · 2017: 5 · 2016: 7 · 2015: 10 · 2014: 4 · 2013: 15 · 2012: 7
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- doxorubicin, PLGA nanoparticles, oral drug delivery, breast cancer, cardiotoxicity, nanoparticle cytotoxicity, cellular uptake, freeze-drying, Caco-2 cells, tumor growth inhibition, antioxidant enzymes, cardiac histopathology
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Antineoplastic Agents, Breast Neoplasms, Creatine Kinase, Doxorubicin, Female, Glutathione, Humans, L-Lactate Dehydrogenase, Malondialdehyde, Polyglycolic Acid, Superoxide Dismutase, Rats, Sprague-Dawley, Microscopy, Atomic Force, Caco-2 Cells, Lactic Acid, Cell Line, Tumor, Mice, Kaplan-Meier Estimate, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model. https://app.cochat.ai/papers/10.1021/mp200011f
- The paper
- Jain, A. K., Swarnakar, N. K., Das, M., Godugu, C., Singh, R. P., Rao, P. R., & Jain, S. (2011). Augmented Anticancer Efficacy of Doxorubicin-Loaded Polymeric Nanoparticles after Oral Administration in a Breast Cancer Induced Animal Model. Molecular Pharmaceutics. https://doi.org/10.1021/mp200011f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.